key: cord-1000168-00rlcbo0
authors: Halaby, Rim; Cuker, Adam; Yui, Jennifer; Matthews, Andrew; Ishaaya, Ella; Traxler, Elizabeth; Domenico, Christopher; Cooper, Tara; Tierney, Ann; Niami, Pardis; van der Rijst, Nathalie; Adusumalli, Srinath; Gutsche, Jacob; Giri, Jay; Pugliese, Steven; Hecht, Todd E. H.; Pishko, Allyson M.
title: Bleeding risk by intensity of anticoagulation in critically ill patients with COVID‐19: A retrospective cohort study
date: 2021-05-07
journal: J Thromb Haemost
DOI: 10.1111/jth.15310
sha: 9a369c9038debcb693f3fb1bfacc98dc92cdc260
doc_id: 1000168
cord_uid: 00rlcbo0

BACKGROUND: Studies report hypercoagulability in coronavirus disease 2019 (COVID‐19), leading many institutions to escalate anticoagulation intensity for thrombosis prophylaxis. OBJECTIVE: To determine the bleeding risk with various intensities of anticoagulation in critically ill patients with COVID‐19 compared with other respiratory viral illnesses (ORVI). PATIENTS/METHODS: This retrospective cohort study compared the incidence of major bleeding in patients admitted to an intensive care unit (ICU) within a single health system with COVID‐19 versus ORVI. In the COVID‐19 cohort, we assessed the effect of anticoagulation intensity received on ICU admission on bleeding risk. We performed a secondary analysis with anticoagulation intensity as a time‐varying covariate to reflect dose changes after ICU admission. RESULTS: Four hundred and forty‐three and 387 patients were included in the COVID‐19 and ORVI cohorts, respectively. The hazard ratio of major bleeding for the COVID‐19 cohort relative to the ORVI cohort was 1.26 (95% confidence interval [CI]: 0.86–1.86). In COVID‐19 patients, an inverse‐probability treatment weighted model found therapeutic‐intensity anticoagulation on ICU admission had an adjusted hazard ratio of bleeding of 1.55 (95% CI: 0.88–2.73) compared with standard prophylactic‐intensity anticoagulation. However, when anticoagulation was assessed as a time‐varying covariate and adjusted for other risk factors for bleeding, the adjusted hazard ratio for bleeding on therapeutic‐intensity anticoagulation compared with standard thromboprophylaxis was 2.59 (95% CI: 1.20–5.57). CONCLUSIONS: Critically ill patients with COVID‐19 had a similar bleeding risk as ORVI patients. When accounting for changes in anticoagulation that occurred in COVID‐19 patients, therapeutic‐intensity anticoagulation was associated with a greater risk of major bleeding compared with standard thromboprophylaxis.

Patients with coronavirus disease 2019 (COVID-19) can develop critical illness and respiratory failure requiring admission to an intensive care unit (ICU). 1 Early reports suggest microvascular thrombosis and venous thromboembolism (VTE) contribute to morbidity and mortality in COVID-19. 2,3 Critical illness is a well-described risk factor for VTE. ICU patients typically receive prophylactic-intensity anticoagulation to prevent this complication. 4 Studies before the COVID-19 pandemic reported approximately 8% to 10% of ICU patients develop VTE despite receiving VTE prophylaxis. 4, 5 Initial reports in patients with COVID-19 suggested a much higher rate of VTE, ranging from 17% to 69%. [6] [7] [8] [9] [10] [11] This prompted some clinicians to increase the intensity of anticoagulation used for VTE prophylaxis in patients with COVID-19 from standard to intermediate or even therapeutic intensity. 12, 13 Potentially because of increased awareness of the thrombotic risks of COVID-19 or use of increased intensity of anticoagulation, more recent data from institutions in the United States reported a lower incidence of thrombosis. 14, 15 Expert guidance on VTE prophylaxis in patients with COVID-19 has varied because of a lack of randomized controlled trials. [16] [17] [18] Patients were excluded from the study if they were admitted to the ICU for a condition unrelated to viral infection or in the absence of respiratory failure. This study was determined to be exempt by the institutional review board at the University of Pennsylvania and a waiver of informed consent was granted for this retrospective study.

The primary endpoint of major bleeding was defined by the criteria of the International Society on Thrombosis and Haemostasis (ISTH) and included fatal bleeding, hemorrhage occurring at a critical area or organ, or bleeding causing a fall in hemoglobin of 2 g/dl or more, or leading to transfusion of 2 or more units of whole blood or red

anticoagulants, COVID-19, critical illness, hemorrhage, thrombosis Essentials • In patients with COVID-19, the bleeding risk associated with increased intensity of anticoagulation for thromboprophylaxis is not well-studied.

• We performed a retrospective cohort study of critically ill patients admitted within a single health system with COVID-19 or other respiratory viral illnesses • Critically ill patients with COVID-19 had a similar risk of bleeding as critically ill patients with other respiratory viral illnesses.

• In COVID-19 patients, therapeutic anticoagulation was associated with an increased risk of bleeding compared to standard thromboprophylaxis. cells. 20 To avoid misclassification of bleeding events from hemodilution or anemia of critical illness, we required the 2 g/dl hemoglobin drop or the 2-unit packed red blood cells transfusion to occur within 24 h of a documented or suspected bleeding event identified on chart review.

Major bleeding was recorded from day of admission to the ICU (time 0) until either hospital discharge, in-hospital death, or data cutoff date (6/30/2020), whichever occurred first. All COVID-19 patients who remained hospitalized at the time of end of study had at least 30 days follow-up from the time of hospital admission. Study data were collected using REDCap (Research Electronic Data Capture) hosted at the University of Pennsylvania. 21, 22 A group of data abstractors reviewed patients' EHR to confirm study eligibility and collect data.

All data abstractors received a guide with detailed instructions on data entry. The first 10% of each abstractors' entries were reviewed in duplicate by one of the lead investigators (A. M. P. or R. H.). If errors in data entry were identified, further instructions were given to the reviewer and additional entries were reviewed in duplicate until consistent agreement. All major bleeding events recorded by data abstractors were verified by one of the lead investigators. Any discrepancies were resolved by discussion between R. H. and A. M. P. We extracted from the EHR the highest intensity of anticoagulant received for each day from ICU admission to discharge/death or data cutoff. When classifying anticoagulation by day, we entered the maximum intensity of anticoagulation received on that day or the day prior. This was done because of expected lags in documentation, with daily progress notes summarizing events of the prior 24 h, including bleeding events occurring the day prior.

Patient characteristics, laboratory values, and intensity of anticoagulation on admission to the ICU were compared between the COVID-19 and ORVI cohorts using standard descriptive statistics.

The proportion of patients who experienced a bleeding event or in-hospital mortality were also compared between the two cohorts using the chi-square test or Fisher's exact test when indicated.

Missing values were not imputed.

Fine and Gray's subdistribution hazard models and cumulative incidence functions were used to compare bleeding outcomes within 30 days of ICU admission between COVID-19 and ORVI patients. Death and hospital discharge were considered competing events. Patients who remained in the hospital beyond 30 days without a bleeding event or remained in the hospital at data cutoff (6/30/2020) were censored.

In the COVID-19 cohort, we assessed the effect of the intensity of anticoagulation received on ICU admission on bleeding risk. We used an inverse probability treatment weighting (IPTW) model to account for potential differences in the severity of illness and/or bleeding risk in patients who received different intensities of anticoagulation. The following laboratory values were considered for inclusion in the model based on prior studies showing an association with bleeding: international normalized ratio, platelet count, creatinine clearance (CrCl), and total bilirubin. 23, 24 We also assessed age ≥65 years, use of antiplatelet agent during hospitalization, as well as indicators of severity of illness (use of extracorporeal membrane oxygenator [ECMO], CRRT, and mechanical ventilation). 24, 25 For each potential variable, we performed univariate analyses predicting time to first bleeding event in Fine and Gray subdistribution hazard models with discharge and death as competing risks. Those variables with p < .05 or with a parameter estimate >2 were included in a logistic regression to develop a propensity score. Patients missing any of the covariates selected for the IPTW model were excluded. Anticoagulation intensity on ICU admission was classified by the maximum intensity of anticoagulation received within 2 days of ICU admission. Patients who did not receive anticoagulation within 2 days of ICU admission were also excluded from the IPTW model. 15 Anticoagulation intensity was entered as a predictor of bleeding using IPTW in a Fine and Gray subdistribution hazard model. We derived cumulative incidence function estimates of bleeding events by anticoagulation intensity.

We expected frequent changes of anticoagulation intensity may occur in patients with COVID-19 because there were changes in institutional guidelines and published work describing increased risk of thrombosis during the study period. Thus, a second competing risk analysis was performed as a sensitivity analysis with anticoagulation intensity as a time-varying covariate. The intensity of anticoagulation was allowed to vary by day and classified as the maximum intensity received on that hospital day or the previous hospital day as described in the section "Classification of anticoagulation intensity." Variables found to be associated with bleeding in our analysis of the whole cohort were entered into the model with anticoagulation intensity as a time-varying covariate.

All analyses were performed using Stata v.14.0 or SAS v.9.4.

In the COVID-19 cohort, 575 unique patients were identified during the period of interest. A total of 443 (77.0%) patients were eligible for inclusion in this study ( Figure 1A ). For the ORVI cohort, 789 unique patients were identified based on ICU admission for acute respiratory failure with positive influenza and/or other respiratory viral polymerase chain reaction during the period of interest. Of these, 387 (49.0%) patients were eligible for inclusion in this study ( Figure 1B ).

The baseline demographic and clinical characteristics of the two cohorts are summarized in Table 1 . There were differences between the two cohorts with respect to race and ethnicity as recorded in the EHR, with fewer White individuals (34.3% vs.

46.5%, p < .001) and more patients of Hispanic/Latino ethnicity (10.6% vs. 2.1%, p < 0.001) in the COVID-19 cohort. Mean (standard deviation) BMI was higher in the COVID-19 cohort compared with the ORVI cohort (31.3 [9.6] kg/m 2 vs. 29.2 [9.6] kg/m 2 , p = 0.002). More ORVI patients were prescribed anticoagulation as outpatients before the index admission (22.5% vs. 14.4%, p = 0.003). Table 2 Table 3 summarizes the intensity of anticoagulation therapy received on admission to the ICU (day 0) and any subsequent increase in anticoagulation intensity from time of ICU admission to hospital discharge or in-hospital death. In the COVID-19 cohort, more patients had at least one increase in intensity of anticoagulation following admission to the ICU compared with the ORVI cohort (59.8% vs. 25 .8%, p < 0.001). The most common reason for increasing intensity of anticoagulation in the COVID-19 cohort was "deterioration in clinical status" (48.2%) in comparison to "atrial fibrillation/flutter" (26.0%) in the ORVI cohort. 11.0 ± 6.9 1 (0.26)

.13 e (Continues) 

The estimated cumulative incidence of major bleeding at 7, 14, and 30 days was 5.2%, 9.8%, and 14.3% in the COVID-19 cohort versus 4.1%, 7.8%, and 11.6% in the ORVI cohort ( Figure 2 

Many studies report an increased thrombotic risk in COVID-19, but few provide a detailed evaluation of bleeding events. 11 A large multiplatform randomized controlled trial paused enrollment for ICU patients with COVID-19 because of futility of therapeutic anticoagulation (NCT04505774). 26 Preliminary results showed therapeutic anticoagulation did not improve hospital survival or days free of organ support compared with usual care pharmacological thromboprophylaxis without difference in major bleeding compared with standard thromboprophylaxis. 27 We performed a methodologically rigorous retrospective study to determine the incidence of major bleeding in critically ill patients with COVID-19.

First, we found that the bleeding risk in COVID-19 was similar to that of other respiratory viral illnesses. Next, we focused on the The clinically most severe event that occurred during the hospitalization is recorded in the following order of severity: fatal bleed >critical organ bleed >packed red blood cell transfusion and/or 2 g/dl hemoglobin drop. c Required 2 g/dl hemoglobin decrease and/or 2-unit pRBC transfusion to occur within 24 h.

d Numbers reflect the presence of bleeding at specific site during the study period (includes first event and recurrent bleeding events if they were at different sites). Patients could have more than one type of major bleeding event. Multiple events of the same type occurring in a single patient are not recorded.

TA B L E 4 ISTH major bleeding events description in the COVID-19 and ORVI cohorts COVID-19 cohort to determine whether the intensity of anticoagulation received was associated with an increased risk of major bleeding. When examining only the anticoagulant received on ICU admission in an IPTW model, we did not find an effect of the intensity of anticoagulation on bleeding risk. 15 However, when we accounted for frequent changes in the anticoagulation intensity after admission to the ICU, we found an increased risk of bleeding among patients on therapeutic versus standard prophylacticintensity anticoagulation.

Prior studies have reported an incidence of major bleeding in COVID-19 patients of approximately 3% to 8% of all patients. 11, 14, 15, 28 The preliminary results of the clinical trial on therapeutic anticoagulation in critically ill COVID-19 patients reported a rate of major bleeding of 3.5% in the therapeutic-intensity anticoagulation arm, though the final results are still pending. 27 Compared with these studies, we found a higher proportion of COVID-19 patients experienced major bleeding events (14.7%).

This is likely because of differences in our study population and design. First, we only studied critically ill patients who likely have a higher bleeding risk than that of ward patients. Second, we also included patients who required ECMO. Third, roughly one-half of the patients in our study received an intensity of anticoagulation higher than standard prophylaxis on admission to the ICU. This is in contrast to some studies, such as Al-Samkari et al., where 86% of patients received standard prophylaxis. 14 Last, we performed chart review to evaluate for bleeding events using the ISTH definition, which differed from some of the other studies that used administrative data or other bleeding definitions (e.g., World

Health Organization definition of major bleeding). Our study findings were more consistent with a single center French study of critically ill COVID patients, where the incidence of hemorrhagic events was 21% patients. 29 Overall, it is difficult to compare bleeding outcomes between studies because of these differences.

A few studies showed the risk of thrombosis is higher in COVID-19 compared with other viral infections. 30 However, to the best of our knowledge, no study compared major bleeding outcomes between COVID-19 and patients with other viral respiratory illnesses. A nationwide cohort using administrative data reported a higher incidence of hemorrhagic stroke in patients with COVID-19 compared to those with influenza infection. 31 In our study, a similar proportion of patients in each cohort experienced an intracranial hemorrhage (1.4% in the COVID-19 cohort and 1.6% in the ORVI cohort).

In our study, when anticoagulation was assessed as a timevarying covariate, we found an increased bleeding risk with therapeutic anticoagulation in the COVID-19 cohort. This is similar to findings in a non-critically ill cohort of patients with COVID-19, in which higher doses of anticoagulation had an incident rate for major or clinically-relevant non-major bleeding of 24 per 100 person-months compared with 6.9 per 100 person-months in patients receiving standard prophylactic-intensity anticoagulation. 32 Another study in critically ill patients with COVID-19 found that two-thirds of major bleeding events occurred while patients were receiving therapeutic-intensity anticoagulation. 33 may suggest consideration of temporarily withholding therapeutic anticoagulation for indications with low daily thrombotic risk (e.g., some patients with atrial fibrillation).

In this study, we did not exclude patients with an episode of major bleeding before ICU admission. Although patients could theoretically have had ongoing bleeding before admission, we believe this would be a rare event as most patients with ongoing or very recent major bleeding would have anticoagulation held and would therefore be excluded from our cohort for not receiving anticoagulation. We did not report prior episodes of major bleeding as a risk factor for bleeding in this study. With retrospective data from a single health system, we could not reliably report if a patient had a previous episode of major bleeding as they may have presented to a hospital outside of our health system. Finally, we anticipated frequent escalations in anticoagulation because many studies during our observation period reported increased thrombotic risk in critically ill patients with COVID-19. 12 Thus, we extracted from the EHR recorded reasons for escalations in anticoagulation intensity. We did not collect data on why anticoagulation intensity was de-escalated. Possible reasons for de-escalation include bleeding or concerns about bleeding risk, need for invasive procedures, diagnostic imaging revealing no thrombosis, or clinical improvement. Further prospective studies are needed to better describe these practice patterns.

Therapeutic anticoagulation was associated with an increased risk of major bleeding compared to standard-intensity thromboprophylaxis in critically-ill patients with COVID-19. The optimal strategy for thromboprophylaxis in COVID-19 critical illness remains unclear.

This real-world study in addition to the early reports of futility from randomized controlled trials question the safety and efficacy of therapeutic anticoagulation in ICU patients with COVID-19.

We acknowledge Emily Schriver, Penn Data Analytics Center (DAC), and the Institute for Biomedical Informatics Clinical Research Informatics Core (CIC) for their assistance with data extraction. 

Comparison of clinical characteristics of patients with asymptomatic vs symptomatic coronavirus disease 2019 in Wuhan, China

Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in Covid-19

COVID-19 and its implications for thrombosis and anticoagulation

American Society of Hematology 2018 guidelines for management of venous thromboembolism: prophylaxis for hospitalized and nonhospitalized medical patients

Dalteparin versus unfractionated heparin in critically Ill patients

Incidence of thrombotic complications in critically ill ICU patients with COVID-19

Confirmation of the high cumulative incidence of thrombotic complications in critically ill ICU patients with COVID-19: an updated analysis

High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study

Incidence of venous thromboembolism in hospitalized patients with COVID-19

Pulmonary embolism in COVID-19 patients: awareness of an increased prevalence

Incidence of VTE and bleeding among hospitalized patients with coronavirus disease 2019: a systematic review and meta-analysis

Anticoagulation practice patterns in COVID-19: a global survey

COVID-19 coagulopathy and thrombosis: analysis of hospital protocols in response to the rapidly evolving pandemic

COVID and coagulation: bleeding and thrombotic manifestations of SARS-CoV2 infection

Anticoagulation, mortality, bleeding and pathology among patients hospitalized with COVID-19: a single health system study

ISTH interim guidance on recognition and management of coagulopathy in COVID-19

Thromboembolism and anticoagulant therapy during the COVID-19 pandemic: interim clinical guidance from the anticoagulation forum

American Society of Hematology 2021 guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19

A minimal common outcome measure set for COVID-19 clinical research

Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Soceity on Thrombosis and Haemostatis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients: definitions of major bleeding in clinical studies

The REDCap Consortium: building an international community of software platform partners

Research electronic data capture (REDCap)-a metadata-driven methodology and workflow process for providing translational research informatics support

Risk factors and impact of major bleeding in critically ill patients receiving heparin thromboprophylaxis

Investigators for the I. factors at admission associated with bleeding risk in medical patients

Extracorporeal membrane oxygenation for severe acute respiratory distress syndrome associated with COVID-19: a retrospective cohort study

Trial of blood thinners pauses enrollment of critically ill COVID-19 patients. National Institute of Health website

Therapeutic anticoagulation in critically ill patients with Covid-19-preliminary report

COVID-19 associated coagulopathy: thrombosis, hemorrhage and mortality rates with an escalated-dose thromboprophylaxis strategy

Thrombotic and hemorrhagic events in critically ill COVID-19 patients: a French monocenter retrospective study

Thrombosis in hospitalized patients with viral respiratory infections versus COVID-19

Comparison of the characteristics, morbidity, and mortality of COVID-19 and seasonal influenza: a nationwide, population-based retrospective cohort study

The hazard of (sub) therapeutic doses of anticoagulants in non-critically ill patients with Covid-19: the Padua province experience

Thrombosis, bleeding, and the observational effect of early therapeutic anticoagulation on survival in critically ill patients with COVID-19

Challenges in the adjudication of major bleeding events in acute coronary syndrome: a plea for a standardized approach and guidance to adjudication

Bleeding risk by intensity of anticoagulation in critically ill patients with COVID-19: A retrospective cohort study